Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 8 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 8 of 8.)

DateHeadlineEventSource5-minTo close
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 GuidancePress releasePR Newswire-1.69%-4.47%
LILLY'S OLUMIANT® (BARICITINIB) NOW AUTHORIZED IN CANADA FOR ADULTS WITH SEVERE ALOPECIA AREATAPress releaseCanada Newswire-0.12%-0.00%
Johna Norton to Retire as Lilly Executive Vice President of Global QualityPress releasePR Newswire+0.23%+0.04%
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial GuidancePress releasePR Newswire-0.11%+1.96%
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter MeetingPress releasePR Newswire-0.00%+0.55%
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifenePress releaseGlobeNewswire-0.14%+0.21%
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™Press releasePR Newswire-0.80%-2.00%
Lilly to Participate in J.P. Morgan Healthcare ConferencePress releasePR Newswire-0.14%+0.66%
Lilly Completes Acquisition of POINT BiopharmaPress releasePR Newswire+0.45%+1.93%
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023Press releasePR Newswire+0.25%+0.00%
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeksPress releasePR Newswire-0.16%+0.34%
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual MeetingPress releasePR Newswire+0.10%+0.47%
Lilly Announces 15% Dividend Increase, First-Quarter 2024 DividendPress releasePR Newswire+0.25%+2.11%
LILLY ANNOUNCES HEALTH CANADA'S AUTHORIZATION OF VERZENIO® (ABEMACICLIB) LABEL EXPANSIONPress releaseCanada Newswire-0.88%-0.00%
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer SymposiumPress releasePR Newswire-0.36%+0.83%
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with ObesityPress releasePR Newswire-0.36%+0.83%
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023Press releasePR Newswire+0.36%+0.61%
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 InhibitorPress releasePR Newswire+0.36%+0.61%
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San DiegoPress releasePR Newswire+0.28%-0.07%
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023Press releasePR Newswire-0.64%-0.13%
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in GermanyPress releasePR Newswire-0.64%-0.13%
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT BiopharmaPress releasePR Newswire-0.25%-3.65%
Lilly to Participate in Evercore ISI HealthCONx ConferencePress releasePR Newswire-0.64%-0.06%
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical ProblemsPress releasePR Newswire+0.11%+3.08%
Lilly Announces Extension of Tender Offer to Acquire POINT BiopharmaPress releasePR Newswire-1.08%-3.06%
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated DisordersPress releaseBusiness Wire-0.42%+0.49%
Form 10-Q ELI LILLY & Co For: Sep 30SEC filing · Form 10-QSEC EDGAR-0.09%+0.48%
Form 8-K ELI LILLY & Co For: Nov 02SEC filing · Form 8-KSEC EDGAR+1.43%+0.26%
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual MeetingPress releasePR Newswire+1.43%+0.26%
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development ActivityPress releasePR Newswire+1.43%+0.26%
MOUNJARO® (TIRZEPATIDE), THE FIRST AND ONLY SINGLE MOLECULE GIP AND GLP-1 RECEPTOR AGONIST FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES IS NOW AVAILABLE IN CANADAPress releaseCanada Newswire+0.03%+0.22%
Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney DiseasePress releasePR Newswire-0.04%-0.10%
Lilly Declares Fourth-Quarter 2023 DividendPress releasePR Newswire-0.04%-0.10%
LILLY CANADA CELEBRATES 85 YEARS AS AN AFFILIATE WHILE THE COMPANY COMMEMORATES THEIR ROLE IN MAKING INSULIN WIDELY AVAILABLE 100 YEARS AGO.Press releaseCanada Newswire-0.11%-0.64%
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative ColitisPress releasePR Newswire+0.24%-0.49%
Lilly to Participate in UBS Biopharma Conference 2023Press releasePR Newswire-0.67%-1.12%
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 20Press releasePR Newswire-1.30%-1.61%
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast CancerPress releasePR Newswire+0.48%-0.92%
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results AnnouncementPress releasePR Newswire-0.41%-1.13%
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two yearsPress releasePR Newswire+0.48%-0.92%
LILLY'S OMVOH™ (MIRIKIZUMAB) NOW AVAILABLE IN CANADA - A FIRST-IN-CLASS TREATMENT FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISPress releaseCanada Newswire-0.39%-1.73%
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeksPress releasePR Newswire+0.21%+0.93%
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 TrialPress releasePR Newswire+0.38%+0.77%
Lilly Announces Details of Presentations at ESMO Congress 2023Press releasePR Newswire+0.83%+3.90%
Lilly Announces Leadership TransitionsPress releasePR Newswire+0.33%+1.12%
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPress releasePR Newswire+0.12%+0.42%
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand TherapiesPress releasePR Newswire-0.42%-2.02%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground